Guidelines on genetic evaluation and management of lynch syndrome: A consensus statement by the US multi-society task force on colorectal cancer

American Journal of Gastroenterology

Volumn 109, Issue 8, 2014, Pages 1159-1179

  Giardiello, Francis M ^a   Allen, John I ^b   Axilbund, Jennifer E ^a   Boland, C Richard ^c   Burke, Carol A ^d   Burt, Randall W ^e   Church, James M ^d   Dominitz, Jason A ^f,g   Johnson, David A ^h   Kaltenbach, Tonya ⁱ   Levin, Theodore R ^j   Lieberman, David A ^k   Robertson, Douglas J ^l,m   Syngal, Sapna ^n,o,p   Rex, Douglas K ^q  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF UTAH   (United States)

^f VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

ⁱ STANFORD UNIVERSITY   (United States)

^j KAISER PERMANENTE MEDICAL CENTER   (United States)

^k OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^l VA MEDICAL CENTER   (United States)

^m DARTMOUTH MEDICAL SCHOOL   (United States)

ⁿ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^o DANA FARBER CANCER INSTITUTE   (United States)

^p HARVARD MEDICAL SCHOOL   (United States)

^q INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADVISORY COMMITTEES; ALGORITHMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; CONSENSUS; DIAGNOSIS, DIFFERENTIAL; EVIDENCE-BASED MEDICINE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; PEDIGREE; UNITED STATES;

EID: 84905595139     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2014.186     Document Type: Article

References (164)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63 : 11-30.
2. Platz EA, Willett WC, Colditz GA et al. Proportion of colorectal cancer risk that might be preventable in a cohort of middle-aged US men. Cancer Causes Control 2000; 11 : 579-88.
3. Lichtenstein P, Holm NV, Verkasalo PK. Environmental and heritable factors in the causation of cancer-analysis of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343 : 78-85.
4. Aaltonen LA, Salovaara R, Kristo P et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening of the disease. N Engl J Med 1998; 338 : 1481-7.
5. Barnetson RA, Tenesa A, Farrington SM et al. Identifi cation and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 2006; 354 : 2751-63.
6. Hampel H, Frankel WL, Martin E et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer. N Engl J Med 2005; 352 : 1851-60.
7. Pinol V, Castells A, Andreu M et al. Gastrointestinal Oncology Group of the Spanish Gastroenterology Association, accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identifi cation of patients with hereditary nonpolyposis colorectal cancer. JAMA 2005; 293 : 1986-94.
8. Salovaara R, Loukkola A, Kristo P et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol 2000; 182 : 193-200.
9. Lynch HT, Shaw MW, Magnuson CW et al. Hereditary factors in cancer. Study of two large midwestern kindreds. Arch Intern Med 1966; 117 : 206-12.
10. Fishel R, Lescoe MK, Rao MRS et al. The human mutator gene homolog hMSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993; 75 : 1027-38.
11. Leach FS, Nicolaides N, Papadopoulos N et al. Mutations of a MutS homolog in hereditary non-polyposis colorectal cancer. Cell 1993; 75 : 1215-55.
12. Papadopoulos N, Nicolaides NC, Wei Y-F et al. Mutation of a mutL homolog in hereditary colon cancer. Science 1994; 263 : 1625-9.
13. Bronner CE, Baker SM, Morrison PT et al. Mutations in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary nonpolyposis colon cancer. Nature 1994; 368 : 258-61.
14. National Cancer Institute. Levels of evidence for cancer genetic studies (PDQ). 2012; Available at: http://www.cancer.gov/cancertopics/pdq/levels- evidence-genetics; Accessed November 1, 2013.
15. Guyatt GH, Oxman AD, Vist GE et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336 : 924-6.
16. Boland CR, Troncale FJ. Familial colonic cancer without antecedent polyposis. Ann Intern Med 1984; 100 : 700-1.
17. Bonadona V, Bonaïti B, Olschwang S et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 2011; 30 : 2304-10.
18. Dunlap MG, Farrington SM, Carothers AD et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 1997; 6 : 105-10.
19. Quehenberger F, Vasen HF, van Houwelingen HC. Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. J Med Genet 2005; 42 : 491-6.
20. Jenkins MA, Baglietto L, Dowty JG et al. Cancer risks for mismatch repair gene mutation carriers: a population-based early onset care-family study. Clin Gastroenterol Hepatol 2006; 4 : 489-98.
21. Alarcon F, Lasset C, Carayol J et al. Estimating cancer risk in HNPCC by the BRL method. Eur J Hum Genet 2007; 15 : 831-6.
22. Baglietto L, Lindor NM, Dowty JG et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst 2010; 102 : 193-201.
23. Choi YH, Cotterchio M, McKeown-Eyssen G et al. Penetrance of colorectal cancer among MLH1/MSH2 carriers participating in the colorectal cancer familial registry in Ontario. Hered Cancer Clin Pract 2009; 7 : 14.
24. Hendriks YM, Wagner A, Morreau H et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 2004; 127 : 17-25.
25. Senter L, Clendenning M, Sotamaa K et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 2008; 135 : 419-28.
26. Hampel H, Frankel WL, Martin E et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 2008; 26 : 5783-8.
27. Vasen HR. Clinical description of the Lynch syndrome [hereditary nonpolyposis colorectal cancer (HNPCC)]. Fam Cancer 2005; 4 : 219-25.
28. Hampel H, Stephens JA, Pukkala E et al. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 2005; 129 : 415-21.
29. Howlader N, Noone AM, Krapcho M et al., (eds. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesda, MD: National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975-2009-pops09/Accessed November 1, 2013.
30. Lynch HT, Smyrk TC, Watson P et al. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an update review. Gastroenterology 1993; 104 : 1535-49.
31. de Vos tot Nederveen Cappel WH, Nagengast FM, Griffioen G et al. Survellance for hereditary nonpolyposis colorectal cancer: a long-term study of 114 families. Dis Colon Rectum 2002; 45 : 1588-94.
32. Parry S, Win AK, Parry B et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut 2011; 60 : 950-7.
33. Win AK, Parry S, Parry B et al. Risk of metachronous colon cancer following surgery for rectal cancer in mismatch repair gene mutation carriers. Ann Surg Oncol 2013; 20 : 1829-36.
34. Edelstein DL, Axilbund JE, Baxter M et al. Rapid development of colorectal neoplasia in patients with Lynch syndrome. Clin Gastroenterol Hepatol 2011; 9 : 340-3.
35. Jass JR, Stewart SM, Stewart J et al. Hereditary nonpolyposis colorectal cancer-morphologies, genes and mutations. Mut Res 1994; 310 : 125-33.
36. Jenkins MA, Hayashi S, O' Shea AM et al. Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population based study. Gastroenterology 2007; 133 : 48-56.
37. Peltomaki P, Offerhaus GJA, Vasen HFA. Lynch syndrome. in: F.T. Bosman, F. Carneiro, R.H. Hruban (Eds.), WHO classifi cation of tumors of the digestive system. Stylus Publishing, Sterling, VA, 2010, pp. 152-5.
38. Gryfe R, Kim H, Hsieh ETK et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000; 342 : 69-77.
39. Aarnio M, Sankila R, Pukkala E et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999; 81 : 214-8.
40. Vasen HR, Stormorken A, Menko FH et al. MSH2 mutation carriers are a higher risk for cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol 2001; 19 : 4074-80.
41. Ponti G, Losi L, Pedroni M et al. Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or kertoacanthomas. J Invest Dermatol 2006; 126 : 2302-7.
42. South CD, Hampel H, Comeras I et al. The frequency of Muir-Torre syndrome among Lynch syndrome families. J Natl Cancer Inst 2008; 100 : 277-81.
43. Watson P, Burzow R, Lynch HT et al. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2001; 82 : 223-8.
44. Barrow E, Robinson L, Alduaij W et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet 2009; 75 : 141-9.
45. Aarnio M, Salovaara R, Aaltonen LA et al. Features of gastric cancer in hereditary non-polyposis colorectal cancer. Int J Cancer 1997; 74 : 551-5.
46. Watson P, Vasen HF, Mecklin JP et al. The risk of extra-colonic, extraendometrial cancer in Lynch syndrome. Int J Cancer 2008; 123 : 444-9.
47. Capelle LG, Van Grieken NC, Lingsma HF et al. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology 2010; 138 : 487-92.
48. Engel C, Loeffler M, Steinke V et al. Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol 2012; 30 : 4409-15.
49. van der Post RS, Kiemeney LA, Ligtenberg MJ et al. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. J Med Genet 2010; 47 : 464-70.
50. Kastrinos F, Stoffel EM, Balmana J et al. Phenotype comparison of MLH1 and MSH2 mutation carriers in a cohort of 1914 individuals undergoing clinical genetic testing in the United States. Cancer Epidemiol Biomarkers Prev 2008; 17 : 2044-51.
51. Win AK, Young JP, Lindor NM. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol 2012; 30 : 958-64.
52. Axilbund JE, Klein AP, Bacon JA et al. Risk of pancreatic cancer in here ditary nonpolyposis colorectal cancer. Insight Meeting, Dusseldorf, Germany, June 24-27 2009.
53. Grindedal EM, Moller P, Eeles R et al. Germ-line mutations in mismatch repair genes associated with prostate cancer. Cancer Epidemiol Biomarkers Prev 2009; 18 : 2460-7.
54. Kastrinos F, Mukherjee B, Tayob N et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA 302; 2009 : 1790-175.
55. Muller A, Edmonston TB, Corao DA et al. Exclusion of breast cancer as an integral tumor of hereditary nonpolyposis colorectal cancer. Cancer Res 2002; 62 : 1014-9.
56. Vasen HF, Morreau H, Nortier JW. Is breast cancer part of the tumor spectrum of hereditary nonpolyposis colorectal cancer? Am J Hum Genet 2001; 68 : 1533-5.
57. Walsh MD, Buchanan DD, Cummings MC et al. Lynch syndrome-associated breast cancers: clinicopathologic characteristics of a case series from the colon cancer family registry. Clin Cancer Res 2010; 16 : 2214-24.
58. Buerki N, Gautier L, Kovac M et al. Evidence for breast cancer as an integral part of Lynch syndrome. Genes Chromosomes Cancer 2012; 51 : 83-91.
59. Raymond VM, Mukherjee B, Wang F et al. Elevated risk of prostate cancer among men with Lynch syndrome. J Clin Oncol 2013; 31 : 1713-8.
60. Gruber SB. Cancer genetics: lesions from colorectal cancer. in: D.P. Kelsen, J.M. Daly, S.E. Kern (Eds.), Gastrointestinal oncology: principles and practice. Lippincott William and Wilkins, Philadelphia, PA, 2002, pp. 1635-1639.
61. Teruya-Feldstein J, Greene J, Cohen L et al. Analysis of mismatch repair defects in the familial occurrence of lymphoma and colorectal cancer. Leuk Lymphoma 2002; 43 : 1619-26.
62. Nilbert M, Therkildsen C, Nissen A et al. Sarcomas associated with hereditary nonpolyposis colorectal cancer: broad anatomical and morphologic spectrum. Fam Cancer 2009; 8 : 209-13.
63. Trimbath JD, Petersen GM, Erdman SH et al. Cafe-au-lait spots and early onset colorectal neoplasia: a variant of HNPCC? Fam Cancer 2001; 1 : 101-5.
64. Durno CA, Holter S, Sherman PM et al. The gastrointestinal phenotype of germline biallelic mismatch repair gene mutations. Am J Gastroenterol 2010; 105 : 2449-56.
65. Vasen HFA, Mecklin JP, Meera Khan P et al. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer. Dis Colon Rect 1991; 34 : 424-5.
66. Vasen HFA, Watson P, Mecklin JP et al. New criteria for hereditary non-polyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC (ICG-HNPCC). Gastroenterology 1999; 116 : 1453-6.
67. Umar A, Boland CR, Terdiman JP et al. Revised Bethesda Guidelines for hereditary polyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96 : 261-8.
68. Mensenkamp AR, Vogelaar IP, van Zelst-Stams WAG et al. Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair defi ciency in Lynch syndrome-like tumors. Gastroenterology 2014; 146 : 643-6.
69. Lindor NM, Rabe K, Petersen GM et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair defi ciency: familial colorectal cancer type X. JAMA 2005; 293 : 1979-85.
70. Mueller-Koch Y, Vogelsang H, Koop R et al. Hereditary nonpolyposis colorectal cancer: Clinical and molecular evidence for a new entity of hereditary colorectal cancer. Gut 2005; 54 : 1733-40.
71. Lior X, Pons E, Xicola RM et al. Differential features of colorectal cancers fulfi lling Amsterdam criteria without involvement of the mutator pathway. Clin Cancer Res 2005; 11 : 7304-10.
72. Valle L, Perea J, Carbonell P et al. Clinicopathologic and pedigree differences in Amsterdam I-positive hereditary nonpolyposis colorectal cancer families according to tumor microsatellite instability status. J Clin Oncol 2007; 25 : 781-6.
73. Lynch HT, Lynch PM, Pester J et al. The cancer family syndrome. Rare cutaneous phenotypic linkage of Torre's syndrome. Arch Intern Med 1981; 141 : 607-11.
74. Entius MM, Keller JJ, Drillenburg P et al. Microsatellite instability and expression of hMLH-1 and hMSH-2 in sebaceous gland carcinomas as markers for Muir-Torre syndrome. Clin Cancer Res 2000; 6 : 1784-9.
75. Hamilton SR, Liu B, Parsons RE et al. The molecular basis of Turcot's syndrome. N Engl J Med 1995; 332 : 839-47.
76. Bronner CE, Baker SM, Morrison PT et al. Mutations in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary nonpolyposis colon cancer. Nature 1994; 368 : 258-61.
77. Nicolaides NC, Papadopoulos N, Liu B et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 1994; 371 : 75-80.
78. Akiyama Y, Sato H, Yamada T et al. Germ-line mutations of hMSH6/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred. Cancer Res 1997; 57 : 3920-3.
79. Miyaki M, Konishi M, Tanaka K et al. Germline mutation of the hMSH6 gene as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet 1997; 17 : 271-2.
80. Kovacs ME, Papp J, Szentirmay Z et al. Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome. Hum Mutat 2009; 30 : 197-203.
81. Lynch HT, Riegert-Johnson DL, Snyder C et al. Lynch syndrome-associated extracolonic tumors are rare in two extended families with the same EPCAM deletion. Am J Gastroenterol 2011; 106 : 1829-36.
82. Kempers MJ, Kuiper RP, Ockeloen CW et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol 2011; 12 : 49-55.
83. Rustgi AK. The genetics of hereditary colon cancer. Genes Dev 2007; 21 : 2525-38.
84. Vaughn CP, Robles J, Swensen JJ et al. Clinical analysis of PMS2: mutation detection and avoidance of pseudogenes. Hum Mutat 2010; 31 : 588-93.
85. Borràs E, Pineda M, Cadiñanos J et al. Refi ning the role of pms2 in Lynch syndrome: germline mutational analysis improved by comprehensive assessment of variants. J Med Genet 2013; 50 : 552-63.
86. Hitchins MP, Ward RL. Constitutional (germline) MLH1 epimutation as an aetiological mechanism for hereditary non-polyposis colorectal cancer. J Med Genet 2009; 46 : 793-802.
87. Aaltonen LA, Peltomaki P, Leach FS et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993; 260 : 812-6.
88. Boland CR, Thibodeau SN, Hamilton SR et al. A National Cancer Institute Workshop of microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58 : 5248-57.
89. Wu Y, Berends MJ, Mensink RG et al. Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 germline mutations. Am J Hum Genet 1999; 65 : 1291-8.
90. Haugen AC, Goel A, Yamada K et al. Genetic instability caused by loss of MutS homologue 3 in human colorectal cancer. Cancer Res 2008; 68 : 8465-72.
91. Lee SY, Chung H, Devaraj B et al. Microsatellite alterations at selected tetranucleotide repeats are associated with morphologies of colorectal neoplasias. Gastroenterology 2010; 139 : 1519-25.
92. Hienonen T, Laiho P, Salovaara R et al. Little evidence for involvement of MLH3 in colorectal cancer predisposition. Int J Cancer 2003; 106 : 292-6.
93. Liu HX, Zhou XL, Liu T et al. The role of hMLH3 in familial colorectal cancer. Cancer Res 2003; 63 : 1894-9.
94. Lindor NM, Burgart LJ, Leontovich O et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 2002; 20 : 1043-8.
95. Cunningham JM, Kim CY, Christensen ER et al. The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal cancers. Am J Hum Genet 2001; 68 : 795-801.
96. Deng G, Bell I, Crawley S et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 2004; 10 : 191-5.
97. Domingo E, Niessen RC, Oliveria C et al. BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene 2005; 24 : 3995-8.
98. Nakagawa H, Nagasake T, Culling HM et al. Efficient molecular screening of Lynch syndrome by specifi c 3 promoter methylation of the MLH1 or BRAF mutation in colorectal cancer with high-frequency microsatellite instability. Oncol Rep 2009; 21 : 1577-83.
99. Balmaña J, Balaguer F, Castellví-Bel S et al. Gastrointestinal Oncology Group of the Spanish Gastroenterological Association, comparison of predictive models, clinical criteria and molecular tumour screening for the identifi cation of patients with Lynch syndrome in a population-based cohort of colorectal cancer patients. J Med Genet 2008; 45 : 557-63.
100. Green RC, Parfrey PS, Woods MO et al. Prediction of Lynch syndrome in consecutive patients with colorectal cancer. J Natl Cancer Inst 2009; 101 : 331-40.
101. Kastrinos F, Allen JI, Stockwell DH et al. Development and validation of a colon cancer risk assessment tool for patients undergoing colonoscopy. Am J Gastroenterol 2009; 104 : 1508-18.
102. Monzon JG, Cremin C, Armstrong L et al. Validation of predictive models for germline mutations in DNA mismatch repair genes in colorectal cancer. Int J Cancer 2010; 126 : 930-9.
103. Boland CR, Shike M. Report from the Jerusalem Workshop on Lynch syndrome-hereditary nonpolyposis colorectal cancer. Gastroenterology 2010; 138 : 2197-201.
104. Barnetson RA, Tenesa A, Farrington SM et al. Identifi cation and survival of carriers of mutations in DNA mismatch-repairs genes in colon cancer. N Engl J Med 2006; 354 : 2751-63.
105. Kastrinos F, Steyerberg EW, Mercado R et al. The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology 2011, 14073-81.
106. Dinh TA, Rosner BI, Atwood JC et al. Health benefi ts and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res 2010; 4 : 9-22.
107. Palomaki GE, McClain MR, Melillo S et al. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 2009, 1142-65.
108. Kastrinos F, Steyerberg EW, Balmaña J et al. Comparison of the clinical prediction model PREMM(1,2,6) and molecular testing for the systematic identifi cation of Lynch syndrome in colorectal cancer. Gut 2013; 62 : 272-9.
109. Juli C, Trésallet C, Brouquet A et al. Identifi cation in daily practice of patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer): revised Bethesda guidelines-based approach versus molecular screening. Am J Gastroenterol 2008; 103 : 2825-35.
110. van Lier MG, Leenen CH, Wagner A et al. Yield of routine molecular analyses in colorectal cancer patients = 70 years to detect underlying Lynch syndrome. J Pathol 2012; 226 : 764-74.
111. Pérez-Carbonell L, Ruiz-Ponte C, Guarinos C et al. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer. Gut 2012; 61 : 865-72.
112. Moreira L, Balaguer F, Lindor N et al. Identifi cation of Lynch syndrome among patients with colorectal cancer. JAMA 2012; 308 : 1555-65.
113. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality for Lynch syndrome in relatives. Genet Med 2009; 11 : 35-41.
114. Ladabaum U, Wang G, Terdiman J et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med 2011; 155 : 69-79.
115. Palomaki GE, McClain MR, Melillo S et al. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality for Lynch syndrome. Genet Med 2009; 11 : 42-65.
116. Mvundura M, Grosse SD, Hampel H et al. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med 2010; 12 : 93-104.
117. Heald B, Plesec T, Liu X et al. Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center. J Clin Oncol 2013; 31 : 1336-40.
118. Stoffel EM, Chitenden A. Genetic testing for hereditary colorectal cancer: challenges in identifying, counseling, and managing high-risk patients. Gastroenterology 2010; 139 : 1436-41.
119. American Gastroenterological Association Medical Position Statement: hereditary colorectal cancer and genetic testing. Gastroenterology 2001; 121 : 195-7.
120. Giardiello FM, Brensinger JD, Petersen GM. AGA technical review on hereditary colorectal cancer and genetic testing. Gastroenterology 2001; 121 : 198-213.
121. Genetic testing for colon cancer: joint statement of the American College of Medical Genetics and American Society of Human Genetics. Joint Test and Technology Transfer Committee Working Group. Genet Med 2000; 2 : 362-6.
122. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Colorectal Cancer Screening. Version 2.2012; http://www.nccn.org/ professionals/physician-gls/PDF/colorectal-screening.pdf. Accessed November 1, 2013.
123. Robson ME, Storm CD, Weitzel J et al. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 2010; 28 : 893-901.
124. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility. J Clin Oncol 1996; 14 : 1730-40.
125. Holtzman NA. Promoting safe and effective genetic testing in the United States: work of the task force on genetic testing. Clin Chem 1999; 45 : 732-8.
126. National Advisory Council for Human Genome Research, Statement on use of DNA testing for presymptomatic identifi cation of cancer risk. J Am Med Assoc 1994; 271 : 785.
127. American College of Surgeons. Commission on Cancer; standard 2.3: risk assessment and genetic counseling. Available at: http://www.facs.org/cancer/ cocsource/2012/february.html#; Accessed November 1, 2013.
128. Trimbath JD, Giardiello FM. Genetic testing and counseling for hereditary colorectal cancer. Aliment Pharmacol Ther 2002; 16 : 1843-57.
129. Järvinen HJ, Mecklin JP, Sistonen P. Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 1995; 108 : 1405-11.
130. Järvinen HJ, Aarnio M, Mustonen H et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000; 118 : 829-34.
131. Järvinen HJ, Renkonen-Sinisalo L, Aktán-Collán K et al. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol 2009; 27 : 4793-7.
132. Dove-Edwin I, Sasieni P, Adams J et al. Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. BMJ 2005; 331 : 1047.
133. Vasen HF, Abdirahman M, Brohet R et al. One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. Gastroenterology 2010; 138 : 2300-6.
134. Engel C, Rahner N, Schulmann K et al. Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. Clin Gastroenterol Hepatol 2010; 8 : 174-82.
135. Stuckless S, Green JS, Morgenstern M et al. Impact of colonoscopic screening in male and female Lynch syndrome carriers with an MSH2 mutation. Clin Genet 2012; 82 : 439-45.
136. Grover S, Sygal S. Risk assessment, genetic testing and management of Lynch syndrome. J NCCN 2010; 8 : 98-105.
137. Lindor NM, Petersen GM, Hadley DW et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 2006, 1507-17.
138. Vasen HFA, Blanco I, Aktan-Collan K et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 2013; 62 : 812-23.
139. Dove-Edwin I, Boks D, GoffS et al. The outcome of endometrial carcinoma surveillance by ultrasound in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer 2002; 94 : 1708-12.
140. Rijcken FE, Mourits MJ, Kleibeuker JH et al. Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2003; 91 : 74-80.
141. Renkonen-Sinisalo L, Butzow R, Leminen A et al. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int J Cancer 2007; 120 : 821-4.
142. Lécuru F, Le Frère Belda MA, Bats AS et al. Performance of office hysteroscopy and endometrial biopsy for detecting endometrial disease in women at risk of human non-polyposis colon cancer: a prospective study. Int J Gynecol Cancer 2008; 18 : 1326-31.
143. Gerritzen LH, Hoogerbrugge N, Oei AL et al. Improvement of endometrial biopsy over transvaginal ultrasound alone for endometrial surveillance in women with Lynch syndrome. Fam Cancer 2009; 8 : 391-7.
144. Stuckless S, Green J, Dawson L et al. Impact of gynecological screening in Lynch syndrome carriers with an MSH2 mutation. Clin Genet 2013; 83 : 359-64.
145. Evans DG, Gaarenstroom KN, Stirling D et al. Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet 2009; 46 : 593-7.
146. Schmeler KM, Lynch HT, Chen LM et al. Prophylactic surgery to reduce the risk of gynecological cancers in Lynch syndrome. N Engl J Med 2006; 354 : 261-9.
147. Yang KY, Caughey AB, Little SE et al. A cost-effectiveness analysis of prophylactic surgery versus gynecologic surveillance for women from hereditary non-polyposis colorectal cancer (HNPCC) families. Fam Cancer 2011; 10 : 535-43.
148. Kwon JS, Sun CC, Peterson SK et al. Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome. Cancer 2008; 113 : 326-35.
149. Renkonen-Sinisalo L, Sipponen P, Aarnio M et al. No support for endoscopic surveillance for gastric cancer in hereditary non-polyposis colorectal cancer. Scand J Gastroenterol 2002; 37 : 574-7.
150. Schulmann K, Brasch FE, Kunstmann E et al. HNPCC-associated small bowel cancer: clinical and molecular characteristics. Gastroenterology 2005; 128 : 590-9.
151. Saurin JC, Pilleul F, Soussan EB et al. Small-bowel capsule endoscopy diagnoses early and advanced neoplasms in asymptomatic patients with Lynch syndrome. Endoscopy 2010; 42 : 1057-62.
152. Myrhøj T, Andersen MB, Bernstein I. Screening for urinary tract cancer with urine cytology in Lynch syndrome and familial colorectal cancer. Fam Cancer 2008; 7 : 303-7.
153. Stoffel E, Mukherjee B, Raymond VM et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology 2009; 137 : 1621-7.
154. Thériault GP, Tremblay CG, Armstrong BG. Bladder cancer screening among primary aluminum production workers in Quebec. J Occup Med 1990; 32 : 869-72.
155. Office of Disease Prevention and Health Promotion. Screening for bladder cancer. Available at: http://odphp.osophs.dhhs.gov/pubs/guidecps/PDF/CH17.PDF; Accessed November 1, 2013.
156. Canto MI, Harinck F, Hruban RH et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer International Cancer of Pancreas Screening (CAPS) Consortium. Gut 2013; 62 : 339-47.
157. Barrow PJ, Ingham S, O' Hara C et al. The spectrum of urological malignancy in Lynch syndrome. Fam Cancer 2013; 12 : 57-63.
158. Haanstra JF, de Vos Tot Nederveen Cappel Gopie WH, Gopie JP et al. Quality of life after surgery for colon cancer in patients with Lynch syndrome: partial versus subtotal colectomy. Dis Colon Rectum 2012; 55 : 653-9.
159. de Vos tot Nederveen Cappel WH, Buskens E, van Duijvendijk P et al. Decision analysis in the surgical treatment of colorectal cancer due to a mismatch repair gene defect. Gut 2003; 52 : 1752-5.
160. Kalady MF, Lipman J, McGannon E et al. Risk of colonic neoplasia after proctectomy for rectal cancer in hereditary nonpolyposis colorectal cancer. Ann Surg 2012; 255 : 1121-5.
161. Burn J, Bishop DT, Mecklin JP et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med 2008; 359 : 2567-78.
162. Mathers JC, Movahedi M, Macrae F et al. Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomized controlled trial. Lancet Oncol 2012; 13 : 1242-9.
163. Burn J, Gerdes AM, Macrae F et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomized controlled trial. Lancet 2011; 378 : 2081-7.
164. Rothwell PM, Fowkes FG, Belch JF et al. Effect of daily aspirin on longterm risk of death due to cancer: analysis of individual patient data from randomized trials. Lancet 2011; 377 : 31-41.